Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.8030 USD
−3.59 M USD
12.04 M USD
3.23 M
About TRACON Pharmaceuticals, Inc.
Sector
CEO
Craig R. Jalbert
Headquarters
San Diego
Website
Founded
2004
FIGI
BBG007TGGHL9
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TCON is 0.0300 USD — it has increased by 1.69% in the past 24 hours. Watch TRACON Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange TRACON Pharmaceuticals, Inc. stocks are traded under the ticker TCON.
TCON stock has fallen by −50.00% compared to the previous week, the month change is a −57.34% fall, over the last year TRACON Pharmaceuticals, Inc. has showed a −99.96% decrease.
TCON reached its all-time high on Mar 3, 2015 with the price of 840,000.0000 USD, and its all-time low was 0.0020 USD and was reached on Jul 31, 2024. View more price dynamics on TCON chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TCON stock is 68.33% volatile and has beta coefficient of 3.77. Track TRACON Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is TRACON Pharmaceuticals, Inc. there?
Today TRACON Pharmaceuticals, Inc. has the market capitalization of 100.52 K, it has decreased by −49.14% over the last week.
Yes, you can track TRACON Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TRACON Pharmaceuticals, Inc. is going to release the next earnings report on Nov 21, 2024. Keep track of upcoming events with our Earnings Calendar.
TCON net income for the last quarter is −2.84 M USD, while the quarter before that showed −3.17 M USD of net income which accounts for 10.39% change. Track more TRACON Pharmaceuticals, Inc. financial stats to get the full picture.
No, TCON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 17.00 employees. See our rating of the largest employees — is TRACON Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRACON Pharmaceuticals, Inc. EBITDA is −9.29 M USD, and current EBITDA margin is −57.15%. See more stats in TRACON Pharmaceuticals, Inc. financial statements.
Like other stocks, TCON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRACON Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRACON Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRACON Pharmaceuticals, Inc. stock shows the sell signal. See more of TRACON Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.